Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults, with an annual incidence of 7-8 cases per 100,000 people per year. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive tumour which can arise in virtually any part of the body, and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with fever, weight loss, and night sweats.
The causes of diffuse large B-cell lymphoma are not well understood. Usually DLBCL arises from normal B cells, but it can also represent a malignant transformation of other types of lymphoma or leukemia. An underlying immunodeficiency, is a significant risk factor. Infection with Epstein-Barr virus has also been found to contribute to the development of some subgroups of DLBCL.
Diagnosis of DLBCL is made by removing a portion of the tumour through a biopsy, and then examining this tissue using a microscope. Usually an experienced hematopathologist makes this diagnosis. Several subtypes of DLBCL have been identified, each having a different clinical presentation and prognosis. However, the usual treatment for each of these is chemotherapy, often in combination with an antibody targeted at the tumour cells. Through these treatments, more than half of patients with DLBCL can be cured, and overall survival for older adults at five years is around 58%.
Diffuse large B-cell lymphoma encompasses a biologically and clinically diverse set of diseases, many of which cannot be separated from one another by well-defined and widely accepted criteria. The World Health Organization (WHO) classification system defines more than a dozen subtypes, each of which can be differentiated based on the location of the tumour, the presence of other cells within the tumour (such as T cells), and whether the patient has certain other illnesses related to DLBCL. One of these well-defined groupings of particular note is "primary mediastinal (thymic) large B-cell lymphoma", which arises within the thymus or mediastinal lymph nodes.
In some cases, a tumour may share many features with both DLBCL and Burkitt lymphoma. In these situations, the tumour is classified as simply “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma”. A similar situation can arise between DLBCL and Hodgkin’s lymphoma; the tumour is then classified as “B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Hodgkin’s lymphoma”.
When a case of DLBCL does not conform to any of the well-defined subtypes, and is also not considered unclassifiable, then it is classified as “diffuse large B-cell lymphoma, not otherwise specified” (DLBCL, NOS). The majority of DLBCL cases fall into this category. Much research has been devoted to separating this still-heterogeneous group; such distinctions are usually made along lines of cellular morphology, gene expression, and immunohistochemical properties.
Within cellular morphology three variants are most commonly seen: centroblastic, immunoblastic, and anaplastic. Most cases of DLBCL are centroblastic, having the appearance of medium-to-large-sized lymphocytes with scanty cytoplasm. Oval or round nuclei containing fine chromatin are prominently visible, having two to four nucleoli within each nucleus. Sometimes the tumour may be monomorphic, composed almost entirely of centroblasts. However, most cases are polymorphic, with a mixture of centroblastic and immunoblastic cells.
Immunoblasts have significant basophilic cytoplasm and a central nucleolus. A tumour can be classified as immunoblastic if greater than 90% of its cells are immunoblasts. This distinction can be problematic, however, because hematopathologists reviewing the microscope slides may often disagree on whether a collection of cells is best characterized as centroblasts or immunoblasts. Such disagreement indicates poor inter-rater reliability.
The third morphologic variant, anaplastic, consists of tumour cells which appear very differently from their normal B cell counterparts. The cells are generally very large with a round, oval, or polygonal shape and pleomorphic nuclei, and may resemble Hodgkin cells or Reed-Sternberg cells.
Gene expression profiling studies have also attempted to distinguish heterogeneous groups of DLBCL from each other. These studies examine thousands of genes simultaneously using a DNA microarray, looking for patterns which may help in grouping cases of DLBCL. Many studies now suggest that cases of DLBCL, NOS can be separated into two groups on the basis of their gene expression profiles; these groups are known as germinal centre B-cell-like (GCB) and activated B-cell-like (ABC). Tumour cells in the germinal centre B-cell-like subgroup resemble normal B cells in the germinal centre closely, and are generally associated with a favourable prognosis. Activated B-cell-like tumour cells are associated with a poorer prognosis, and derive their name from studies which show the continuous activation of certain pathways normally activated when B cells interact with an antigen. The NF-κB pathway, which is normally involved in transforming B cells into plasma cells, is an important example of one such pathway.
Another notable finding of recent gene expression studies is the importance of the cells and microscopic structures interspersed between the malignant B cells within the DLBCL tumor, an area commonly known as the tumour microenvironment. The presence of gene expression signatures commonly associated with macrophages, T cells, and remodelling of the extracellular matrix seems to be associated with an improved prognosis and better overall survival. Alternatively, expression of genes coding for pro-angiogenic factors is correlated with poorer survival.
With the apparent success of gene expression profiling in separating biologically distinct cases of DLBCL, NOS, some researchers examined whether a similar distinction could be made using immunohistochemical staining (IHC), a widely used method for characterizing tissue samples. This technique uses highly specific antibody-based stains to detect proteins on a microscope slide, and since microarrays are not widely available for routine clinical use, IHC is a desirable alternative. Many of these studies focused on stains against the products of prognostically significant genes which had been implicated in DLBCL gene expression studies. Examples of such genes include BCL2, BCL6, MUM1, LMO2, MYC, and p21. Several algorithms for separating DLBCL cases by IHC arose out of this research, categorizing tissue samples into groups most commonly known as GCB and non-GCB. The correlation between these GCB/non-GCB immunohistochemical groupings and the GCB/ABC groupings used in gene expression profiling studies is uncertain, as is their prognostic value. This uncertainty may arise in part due to poor inter-rater reliability in performing common immunohistochemical stains.
The most typical symptom at the time of diagnosis is a mass that is rapidly enlarging and located in a part of the body with multiple lymph nodes.
Standard treatment is CHOP-R, also referred to as R-CHOP, an improved form of CHOP with the addition of rituximab (Rituxan), which has increased the rates of complete responses for DLBCL patients, particularly elderly patients. R-CHOP is a combination of one monoclonal antibody, 3 chemotherapy drugs, and one steroid: rituximab (Rituxan), cyclophosphamide (Cytoxan) doxorubicin (Hydroxydaunorubicin), vincristine (Oncovin), and prednisone.Chemotherapy is administered intravenously and is most effective when it is administered multiple times over a period of months (e.g. every 3 weeks, over 6 to 8 cycles). The number of cycles of chemotherapy given depends on the stage of the disease. patients with limited stage disease receive 3 cycles of therapy, while patients with extensive disease 6 or 8 cycles of chemotherapy. In the United States, 6 cycles is the preferred approach rather than 8 cycles. A new development is obtaining a PET scan after completing two cycles of chemotherapy, to help make further decisions after chemotherapy.
Older people are not able to tolerate therapy well. Muliple lower intensity regimens have been attempted in this age group.
Radiation is often added in the treatment. It is used commonly after completing 3 cycles of treatment in limited stage disease. In extensive disease, radiation can be used at the end of the treatment, after 6-8 cycles of chemotherapy, to areas of bulky involvement. Radiation therapy alone is not an effective treatment for this disease.
The germinal-center subtype has the best prognosis, with 66.6% of treated patients surviving more than five years. The IPI score is used in prognosis in clinical practice. Lenalidomide has been recently shown to improve outcomes in the non-germinal center subtype. 
For children with diffuse large B-cell lymphomas, most studies have found 5-year survival rates ranging from about 70% to more than 90%.
A second regimen under evaluation is R-EPOCH (rituximab with etoposide-prednisone-vincristine-doxorubicin-cyclophosphamide), which demonstrated a 5-year progression-free survival (PFS) of 79% in a phase II trial. A phase III trial, CALGB 50303, is now comparing R-EPOCH with R-CHOP in patients with newly diagnosed DLBCL.
^"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project". Blood89 (11): 3909–3918. 1997. PMID9166827. edit
^Vinay Kumar; Abul K. Abbas; Nelson Fausto; Jon C. Aster (28 May 2009). Robbins & Cotran Pathologic Basis of Disease. Elsevier Health Sciences. p. 607. ISBN978-1-4377-2015-0.Cite uses deprecated parameters (help)
^Arnold S. Freeman; Jon C. Aster (2012). "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma". In Denise S. Basow. UpToDate. Waltham, MA: UpToDate. Retrieved 15 August 2012.
^Swerdlow, S.H.; Campo, E.; Jaffe, E.S. et al., eds. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC. p. 233. ISBN978-92-832-2431-0.|displayeditors= suggested (help)
^Akyurek, N.; Uner, A.; Benekli, M.; Barista, I. (2011). "Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab". Cancer118 (17): 4173–83. doi:10.1002/cncr.27396. PMID22213394. edit
^Feugier, P.; Van Hoof, A.; Sebban, C.; Solal-Celigny, P.; Bouabdallah, R.; Fermé, C.; Christian, B.; Lepage, E.; Tilly, H.; Morschhauser, F.; Gaulard, P.; Salles, G.; Bosly, A.; Gisselbrecht, C.; Reyes, F.; Coiffier, B. (2005). "Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte". Journal of Clinical Oncology23 (18): 4117–4126. doi:10.1200/JCO.2005.09.131. PMID15867204. edit
^ abAlizadeh, A. A.; Eisen, M. B.; Davis, R. E.; Ma, C.; Lossos, I. S.; Rosenwald, A.; Boldrick, J. C.; Sabet, H.; Tran, T.; Yu, X.; Powell, J. I.; Yang, L.; Marti, G. E.; Moore, T.; Hudson Jr, J.; Lu, L.; Lewis, D. B.; Tibshirani, R.; Sherlock, G.; Chan, W. C.; Greiner, T. C.; Weisenburger, D. D.; Armitage, J. O.; Warnke, R.; Levy, R.; Wilson, W.; Grever, M. R.; Byrd, J. C.; Botstein, D.; Brown, P. O. (2000). "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling". Nature403 (6769): 503–511. doi:10.1038/35000501. PMID10676951. edit
^Shipp, M. A.; Ross, K. N.; Tamayo, P.; Weng, A. P.; Kutok, J. L.; Aguiar, R. C. T.; Gaasenbeek, M.; Angelo, M.; Reich, M.; Pinkus, G. S.; Ray, T. S.; Koval, M. A.; Last, K. W.; Norton, A.; Lister, T. A.; Mesirov, J.; Neuberg, D. S.; Lander, E. S.; Aster, J. C.; Golub, T. R. (2002). "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning". Nature Medicine8 (1): 68–74. doi:10.1038/nm0102-68. PMID11786909. edit
^Rosenwald, A.; Wright, G.; Chan, W. C.; Connors, J. M.; Campo, E.; Fisher, R. I.; Gascoyne, R. D.; Muller-Hermelink, H. K.; Smeland, E. B.; Giltnane, J. M.; Hurt, E. M.; Zhao, H.; Averett, L.; Yang, L.; Wilson, W. H.; Jaffe, E. S.; Simon, R.; Klausner, R. D.; Powell, J.; Duffey, P. L.; Longo, D. L.; Greiner, T. C.; Weisenburger, D. D.; Sanger, W. G.; Dave, B. J.; Lynch, J. C.; Vose, J.; Armitage, J. O.; Montserrat, E.; López-Guillermo, A. (2002). "The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma". New England Journal of Medicine346 (25): 1937–1947. doi:10.1056/NEJMoa012914. PMID12075054. edit
^Linderoth, J.; Edén, P.; Ehinger, M.; Valcich, J.; Jerkeman, M.; Bendahl, P. R. O.; Berglund, M.; Enblad, G.; Erlanson, M.; Roos, G. R.; Cavallin-Ståhl, E. (2008). "Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma". British Journal of Haematology141 (4): 423–432. doi:10.1111/j.1365-2141.2008.07037.x. PMID18419622. edit
^ abDe Jong, D.; Xie, W.; Rosenwald, A.; Chhanabhai, M.; Gaulard, P.; Klapper, W.; Lee, A.; Sander, B.; Thorns, C.; Campo, E.; Molina, T.; Hagenbeek, A.; Horning, S.; Lister, A.; Raemaekers, J.; Salles, G.; Gascoyne, R. D.; Weller, E. (2008). "Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)". Journal of Clinical Pathology62 (2): 128–138. doi:10.1136/jcp.2008.057257. PMID18794197. edit
^ abChoi, W. W. L.; Weisenburger, D. D.; Greiner, T. C.; Piris, M. A.; Banham, A. H.; Delabie, J.; Braziel, R. M.; Geng, H.; Iqbal, J.; Lenz, G.; Vose, J. M.; Hans, C. P.; Fu, K.; Smith, L. M.; Li, M.; Liu, Z.; Gascoyne, R. D.; Rosenwald, A.; Ott, G.; Rimsza, L. M.; Campo, E.; Jaffe, E. S.; Jaye, D. L.; Staudt, L. M.; Chan, W. C. (2009). "A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy". Clinical Cancer Research15 (17): 5494–5502. doi:10.1158/1078-0432.CCR-09-0113. PMID19706817. edit
^Colomo, L.; López-Guillermo, A.; Perales, M.; Rives, S.; Martínez, A.; Bosch, F.; Colomer, D.; Falini, B.; Montserrat, E.; Campo, E. (2002). "Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma". Blood101 (1): 78–84. doi:10.1182/blood-2002-04-1286. PMID12393466. edit
^ abHans, C. P.; Weisenburger, D. D.; Greiner, T. C.; Gascoyne, R. D.; Delabie, J.; Ott, G.; Müller-Hermelink, H. K.; Campo, E.; Braziel, R. M.; Jaffe, E. S.; Pan, Z.; Farinha, P.; Smith, L. M.; Falini, B.; Banham, A. H.; Rosenwald, A.; Staudt, L. M.; Connors, J. M.; Armitage, J. O.; Chan, W. C. (2004). "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray". Blood103 (1): 275–282. doi:10.1182/blood-2003-05-1545. PMID14504078. edit
^Muris, J. J. F.; Meijer, C.; Vos, W.; Van Krieken, J.; Jiwa, N. M.; Ossenkoppele, G. J.; Oudejans, J. J. (2006). "Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma". The Journal of Pathology208 (5): 714–723. doi:10.1002/path.1924. PMID16400625. edit
^Cultrera JL, Dalia SM (July 2012). "Diffuse large B-cell lymphoma: current strategies and future directions". Cancer Control19 (3): 204–13. PMID22710896.